105 related articles for article (PubMed ID: 8744564)
1. HIV-1 candidate vaccines can induce antibodies which share specificity with human monoclonal antibodies capable of neutralizing primary isolates.
Davis D
Vaccine; 1996 Mar; 14(4):353-4. PubMed ID: 8744564
[No Abstract] [Full Text] [Related]
2. Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
Haynes BF; Moody MA; Verkoczy L; Kelsoe G; Alam SM
Hum Antibodies; 2005; 14(3-4):59-67. PubMed ID: 16720975
[TBL] [Abstract][Full Text] [Related]
3. The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases.
Donners H; Vermoesen T; Willems B; Davis D; van der Groen G
Vaccine; 2003 Dec; 22(1):104-11. PubMed ID: 14604577
[TBL] [Abstract][Full Text] [Related]
4. HIV vaccine design and the neutralizing antibody problem.
Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
[No Abstract] [Full Text] [Related]
5. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
Burton DR; Pyati J; Koduri R; Sharp SJ; Thornton GB; Parren PW; Sawyer LS; Hendry RM; Dunlop N; Nara PL
Science; 1994 Nov; 266(5187):1024-7. PubMed ID: 7973652
[TBL] [Abstract][Full Text] [Related]
6. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
Parren PW; Moore JP; Burton DR; Sattentau QJ
AIDS; 1999; 13 Suppl A():S137-62. PubMed ID: 10885772
[No Abstract] [Full Text] [Related]
7. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
8. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1.
Xiao Y; Dong X; Chen Y
Int Arch Allergy Immunol; 2000 Aug; 122(4):287-92. PubMed ID: 10971120
[TBL] [Abstract][Full Text] [Related]
9. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.
Montefiori DC; Evans TG
AIDS Res Hum Retroviruses; 1999 May; 15(8):689-98. PubMed ID: 10357464
[No Abstract] [Full Text] [Related]
10. HIV Broadly Neutralizing Antibodies: VRC01 and Beyond.
Wu X
Adv Exp Med Biol; 2018; 1075():53-72. PubMed ID: 30030789
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.
Hioe CE; Xu S; Chigurupati P; Burda S; Williams C; Gorny MK; Zolla-Pazner S
Int Immunol; 1997 Sep; 9(9):1281-90. PubMed ID: 9310831
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of HIV-1 by antibody.
Sattentau QJ
Curr Opin Immunol; 1996 Aug; 8(4):540-5. PubMed ID: 8794008
[TBL] [Abstract][Full Text] [Related]
13. Induction of monoclonal antibody with predefined ELNKWA epitope specificity by epitope vaccine.
Xiao Y; Dong XN; Chen YH
Hybridoma; 2000 Aug; 19(4):347-50. PubMed ID: 11001409
[TBL] [Abstract][Full Text] [Related]
14. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
15. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.
He Y; Honnen WJ; Krachmarov CP; Burkhart M; Kayman SC; Corvalan J; Pinter A
J Immunol; 2002 Jul; 169(1):595-605. PubMed ID: 12077293
[TBL] [Abstract][Full Text] [Related]
16. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 neutralizing antibodies: how full is the bottle?
Moore JP; Burton DR
Nat Med; 1999 Feb; 5(2):142-4. PubMed ID: 9930854
[No Abstract] [Full Text] [Related]
18. Pushing the envelope on HIV-1 neutralization.
Joyce JG; ter Meulen J
Nat Biotechnol; 2010 Sep; 28(9):929-31. PubMed ID: 20829830
[No Abstract] [Full Text] [Related]
19. HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis.
Wills S; Hwang KK; Liu P; Dennison SM; Tay MZ; Shen X; Pollara J; Lucas JT; Parks R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Thomas R; Kim JH; Michael NL; Robb ML; McRaven M; Montefiori DC; Hope TJ; Liao HX; Moody MA; Ferrari G; Haynes BF; Alam SM; Bonsignori M; Tomaras GD
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321320
[TBL] [Abstract][Full Text] [Related]
20. Serological responses to candidate AIDS vaccines.
Graham BS
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S145-8. PubMed ID: 7865290
[No Abstract] [Full Text] [Related]
[Next] [New Search]
